ÍøºìºÚÁÏ

Skip to main content
(352) 273-9120

Biljana Horn, MD

Pediatric Hematologist/Oncologist (Child Cancer Specialist)

Photo of Biljana Horn
(352) 273-9120 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • Hematopoietic Stem Cell Transplantation , 34 publications
  • Graft vs Host Disease , 12 publications
  • Transplantation Conditioning , 11 publications
  • Transplantation, Homologous , 10 publications

Research activity

60 publications

1,620 citations

Why is this important?

Active clinical trials

BMT12108, Non-Myeloablative Conditioning and Bone Marrow Transplantation

Allogeneic blood or marrow transplantation (alloBMT) is a curative therapy for a variety of hematologic disorders, including sickle cell disease and thalassemia. Even when it is clear that alloBMT can give to these patients an improvement in their…

Investigators
Jordan Milner, Biljana Horn
Status
Accepting Candidates
Ages
1 Year - 70 Years
Sexes
All
Conditioning SCID Infants Diagnosed Early (CSIDE)

The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune…

Investigators
Jordan Milner, Biljana Horn
Status
Accepting Candidates
Ages
0 Years - 2 Years
Sexes
All

My publications

60 publications

2025

Evolution of the Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (FPBCC): A Statewide Initiative Toward Improving Transplant Outcomes.

Pediatric transplantation

•

2024

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood

2024

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report.

Leukemia research reports

•

2024

The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.

Pediatric transplantation

•

2023

Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders

Pediatric Blood & Cancer